Opinion of the Transparency Council – bisoprolol

At its meeting on 19 September 2022 the Transparency Council adopted opinion No. 142/2022 on the inclusion in the drug reimbursement procedure of medicines containing the active substance bisoprolol in the scope of indications for use or posology or route of administration other than those specified in the Summary of Product Characteristics.

Publication with the minutes of the Transparency Council meeting